FINWIRES · TerminalLIVE
FINWIRES

Equities Mostly Rise Intraday Amid Tech Boost, With Trump's China Visit in Focus

By
Equities Mostly Rise Intraday Amid Tech Boost, With Trump's China Visit in Focus

US benchmark equity indexes were mostly higher intraday as several key technology stocks advanced, while President Donald Trump landed in China for a high-stakes state visit.

The Nasdaq Composite was up 1.2% at 26,405.4 after midday Wednesday, while the S&P 500 rose 0.6% to 7,448.4. The Dow Jones Industrial Average fell 0.3% to 49,616.8. Among sectors, communication services paced the gainers, followed by tech, while utilities saw the steepest decline.

Chipmaking giant Nvidia's (NVDA) shares were up 2.7%, the second-best performer on the Dow. Other major tech stocks Apple (AAPL), Amazon.com (AMZN), and Cisco Systems (CSCO) were also in the green. Cisco is scheduled to report its latest quarterly financial results after the closing bell Wednesday.

On Semiconductor (ON) shares jumped 10% intraday, the second-biggest gainer on the S&P 500.

Trump reportedly arrived in Beijing Wednesday for a highly anticipated meeting with his Chinese counterpart, Xi Jinping.

"The trip underscores the stakes for chips, tech, and the (artificial intelligence) supply chain highlighted by Nvidia's most advanced chips, which (have) faced a series of tightening US export restrictions on China sales," Wedbush Securities said in note.

Nvidia Chief Executive Jensen Huang, Apple's Tim Cook, and Tesla (TSLA) CEO Elon Musk are accompanying Trump on the visit, along with other top US tech executives, according to media reports.

"We believe that this summit will prove 'constructive' as it keeps the conversation focused on reopening channels where possible rather than allowing the relationship to drift into a more permanent Cold War dynamic that would ultimately slow AI diffusion and cloud monetization on both sides," Wedbush said.

US Treasury yields were mixed intraday, with the 10-year rate up 1.1 basis points at 4.48% and the two-year rate little changed at 4%.

In economic news, US producer prices in April rose at the fastest pace in four years as broad-based increases in services and goods signaled intensifying inflation pressures, official data showed.

"On the heels of yesterday's disappointing (consumer price index) results, the April producer price report flags intense inflation pressure in the pipeline," BMO Capital Markets said in a note. "Look for another heated consumer inflation report in May, and not solely due to costlier gasoline, as price pressures stemming from the Iran war are bleeding into other sectors of the economy."

West Texas Intermediate crude was down 0.3% at $101.84 a barrel intraday, while Brent fell 1.5% to $106.21.

The International Energy Agency forecast a sharper decline in global oil demand this year than previously expected as the Middle East conflict drives up energy prices.

"More than 10 weeks after the war in the Middle East began, mounting supply losses from the Strait of Hormuz are depleting global oil inventories at a record pace," according to the report.

Separately, the Organization of the Petroleum Exporting Countries reduced its global oil demand growth outlook for 2026, but upgraded its projection for next year.

Trump recently rejected Iran's counteroffer to end the war, though a fragile ceasefire between the two countries still holds. Trump recently told reporters that "we have Iran very much under control."

"That control, however, does not extend to the Strait of Hormuz, which remains effectively closed with both Iran and the US maintaining naval blockades," Saxo Bank said in a report Wednesday.

In company news, Wix.com (WIX) logged a larger-than-expected annual decline in its first-quarter earnings, while the Israeli web development platform maintained its full-year outlook. The company's US-listed shares tanked nearly 26% intraday.

Gold was up 0.4% at $4,705.80 per troy ounce, while silver climbed 4.8% to $89.69 per ounce.

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP